Stallergenes completes enrollment in Phase III trial of dust mite allergy tablet Actair

Stallergenes Greer plc (Euronext:STAGR) completed enrollment of over 1,600 patients in a Phase III trial of once-daily Actair house dust mites sublingual tablet (S-524101, STG320) to treat house dust mite-induced allergic rhinitis. The double-blind, placebo-controlled, international trial's primary endpoint is total combined rhinitis symptom score and daily rescue medication score. The secondary endpoint is safety...